CCO Independent Conference Highlights of the 2023 SABCS Annual Meeting *

Review a conference preview commentary on experts’ abstracts to watch, Capsule Summary slidesets, and an expert analysis of key studies from the 2023 Breast Cancer Symposium.

Share

Program Content

Activities

SABCS 2023 Preview
An Expert’s Guide to SABCS 2023: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2023

View Activity
12 Capsule Summary Slides

Activities

KEYLYNK-009
KEYLYNK-009: Phase II Trial of Maintenance Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy in Untreated Metastatic or Locally Recurrent Inoperable TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

View Activity
KEYNOTE-756
KEYNOTE-756: Phase III Trial of Neoadjuvant Pembrolizumab vs Placebo Plus CT Followed by Adjuvant Pembrolizumab vs Placebo Plus ET in High-Risk, ER+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

View Activity
ALEXANDRA/Impassion030
ALEXANDRA/IMpassion030: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab for Stage II/III Triple-Negative Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2023

View Activity
CheckMate 7FL Biomarkers
Phase III CheckMate 7FL: Biomarker Analysis of Addition of Nivolumab vs Placebo to Neoadjuvant CT and Adjuvant ET in High-Risk ER+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2023

View Activity
HER2CLIMB-02
HER2CLIMB-02: Phase III Trial of Trastuzumab Emtansine ± Tucatinib in Previously Treated HER2-Positive MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2023

View Activity
NSABPB51/RTOG 1304
NRG Oncology/NSABP B-51/RTOG 1304: Phase III Trial Evaluating Benefit of Adjuvant Regional Nodal Irradiation in Patients With Early Breast Cancer Converting to Axillary Lymph Node Negativity After Neoadjuvant Chemotherapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2023

View Activity
DEBBRAH – LMC Cohort
Phase II DEBBRAH: Trastuzumab Deruxtecan in Cohort With HER2+/HER-Low ABC and Leptomeningeal Carcinomatosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2023

View Activity
TROPiCS-02 Subgroup Analysis by Age
TROPiCS-02 Subgroup Analysis by Age: Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2023

View Activity
NATALEE Adj Ribociclib
Final iDFS Analysis of NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor in HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

View Activity
Neo N
BCT1902/IBCSG 61-20 Neo-N: Phase II Trial of Concurrent Nivolumab Plus Neoadjuvant Chemotherapy With and Without Lead-In Nivolumab in Stage I/II TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

View Activity
monarchE Profiling and ctDNA
monarchE: Molecular Profiling of Primary Tumor Tissue and ctDNA Detection in Patients With High-Risk, Node-Positive HR+/HER2- EBC Treated With Adjuvant ET ± Abemaciclib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

View Activity
TROPIONBreast01
TROPION-Breast01: Efficacy and Safety From Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

View Activity

Activities

2023 SABCS Highlights
Highlights From the 2023 San Antonio Breast Cancer Symposium
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 23, 2024

Expires: February 22, 2025

View Activity

Faculty

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head
Division of Hematology and Oncology
Department of Medicine
UW Medicine
Senior Vice President
Clinical Research Division Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.